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ABSTRACT: The hydroxylation or epoxidation of hydrocarbons by
bacterial multicomponent monooxygenases (BMMs) requires the interplay
of three or four protein components. How component protein interactions
control catalysis, however, is not well understood. In particular, the binding
sites of the reductase components on the surface of their cognate
hydroxylases and the role(s) that the regulatory proteins play during
intermolecular electron transfer leading to the hydroxylase reduction have
been enigmatic. Here we determine the reductase binding site on the
hydroxylase of a BMM enzyme, soluble methane monooxygenase
(sMMO) from Methylococcus capsulatus (Bath). We present evidence that the ferredoxin domain of the reductase binds to
the canyon region of the hydroxylase, previously determined to be the regulatory protein binding site as well. The latter thus
inhibits reductase binding to the hydroxylase and, consequently, intermolecular electron transfer from the reductase to the
hydroxylase diiron active site. The binding competition between the regulatory protein and the reductase may serve as a control
mechanism for regulating electron transfer, and other BMM enzymes are likely to adopt the same mechanism.
■ INTRODUCTION
Bacterial multicomponent monooxygenases (BMMs) comprise
a family of enzymes capable of hydroxylating or epoxidizing a
wide range of hydrocarbons, including the greenhouse gas
methane and environmentally hazardous substances such as
benzene and trichloroethylene.1,2 BMM enzymes can be
grouped into four classes: the three-component enzymes
soluble methane monooxygenases (sMMOs), phenol hydrox-
ylases (PHs), and alkene monooxygenases (AMOs), and the
four-component enzymes alkene/arene monooxygenases.1 All
BMM enzymes contain three common components: a
hydroxylase, a reductase, and a regulatory protein. Alkene/
arene monooxygenases require an additional Rieske protein for
reducing the hydroxylase.1−4 The hydroxylase component is a
multi-subunit dimeric (α2β2γ2 or α2β2) protein hosting a diiron
center in each α-subunit. The carboxylate-bridged diiron center
is the locus for O2 activation and subsequent substrate
hydroxylation/epoxidation.3,4 It is similar to those in the R2
subunit of ribonucleotide reductase,5 ferritin,6 stearoyl acyl
carrier protein Δ9 desaturase,7,8 and the aging-related protein
Clk1.9,10 The reductase component is an NADH oxido-
reductase with an [Fe2S2] cluster in the ferredoxin domain
(Fd) and a ﬂavin adenine dinucleotide (FAD) cofactor in the
FAD domain, responsible for the reduction of the hydroxylase
diiron center. The ultimate electron source is reduced
nicotinamide adenine dinucleotide (NADH).11,12 The third
component, a cofactor-less regulatory protein, couples NADH
consumption to product formation.2,13,14 A key question
regarding the catalytic mechanism of BMM enzymes is how
component protein interactions achieve the timely control of
electron transfer to the diiron active site, dioxygen activation,
and hydrocarbon substrate oxidation.
Elucidating component protein binding sites on the
hydroxylase is required as a foundation for answering such a
question. An important clue comes from early crystallographic
investigations of hydroxylases from the three-component
system sMMO15,16 and the four-component toluene/o-xylene
monooxygenase (ToMO).17 Both hydroxylases contain a
structure of C2 symmetry with a shallow depression, termed
the “canyon”, on each side of the protein dimer (Figure 1a).
The canyon region was proposed as the docking site for the
other component proteins,15,17 and, indeed, later crystallo-
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Figure 1. Crystal structure of the hydroxylase−regulatory protein
complex of sMMO (PDB ID 4GAM): (a) the hydroxylase MMOH
showing the canyon, and (b) MMOH in complex with the regulatory
protein MMOB. There is another MMOB molecule binding to the
canyon on the other side of MMOH. MMOH α-subunit is colored in
green, β-subunit in blue, γ-subunit in yellow, and MMOB in purple.
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graphic studies revealed that the regulatory component does
occupy a portion of the canyon in hydroxylase−regulatory
protein complexes of PH,18 toluene-4-monooxygenase (T4mO,
another four-component BMM),19 and, very recently, sMMO
(Figure 1b).20
The exact binding site of the reductase component has
remained elusive, however. There is no crystal structure
available for the hydroxylase−reductase complex of any BMM
enzyme. By using the zero-length cross-linker 1-ethyl-3-(3-
(dimethylamino)propyl)carbodiimide (EDC), a chemical cross-
linking study of sMMO isolated from Methylosinus tricho-
sporium OB3b revealed that the reductase, MMOR, cross-
linked to the β-subunit of the hydroxylase MMOH, and that
the regulatory component, MMOB, cross-linked to the α-
subunit.21 A diﬀerent result was obtained, however, using
sMMO isolated from Methylococcus capsulatus (Bath), where
either the full-length MMOR or its Fd cross-linked to the α-
subunit using the same cross-linker, EDC.22 Further attempts
to determine the binding site by identifying cross-linked
residues failed. The two identiﬁed Fd cross-linking sites, Glu-56
and Glu-91, cross-linked to the N-terminal amino group of
MMOH α-subunit, which is not observed in the crystal
structure of MMOH owing to disorder.22
Because the MMOR binding site on MMOH is obscure, it
was unclear how the regulatory protein and the reductase might
interact in the complete enzyme system. Simulations of steady-
state oxidase and oxygenase activities of sMMO as a function of
component protein concentrations favored a non-competitive
model, whereby MMOR and MMOB bind at distinct sites on
MMOH,23 forming a hypothetical ternary complex. The
formation of such a ternary complex was also proposed in a
small-angle X-ray scattering (SAXS) study, where the species
formed in the presence of large excess of MMOB and MMOR
(10−20 equiv of each relative to MMOH) was modeled as a
MMOH−2MMOB−2MMOR complex.24 Later crystallo-
graphic investigations of the hydroxylase−regulatory protein
complexes, however, suggested that the regulatory component
may block the reductase binding site,18−20 but there was no
direct experimental evidence for such. The role of the
regulatory protein in electron transfer from the reductase to
the hydroxylase diiron center is also not well understood. A
determination of the reductase binding site on the hydroxylase
would clarify many of these questions.
Accordingly, in this study we determined the reductase
binding site on the hydroxylase of sMMO isolated from
Methylococcus capsulatus (Bath), by using hydrogen−deuterium
exchange coupled to mass spectrometry (HDX-MS). The
results clearly reveal that the Fd of MMOR indeed binds to the
canyon of MMOH. More importantly, the Fd shares the same
binding site as the core of MMOB; it therefore binds
competitively with MMOB to MMOH. These conclusions are
supported by computational docking and by binding
competition assays. Consistent with the shared binding site,
we show that MMOB does not facilitate, but actually inhibits,
electron transfer. Overall, this work presents the ﬁrst
experimentally determined reductase Fd binding site on the
hydroxylase of a BMM enzyme, and it reveals how the
regulatory component may control electron transfer in the
catalytic cycle.
■ EXPERIMENTAL SECTION
Materials. D2O was ordered from Cambridge Isotope Laboratories.
5-({2-[(Iodoacetyl)amino]ethyl}amino)naphthalene-1-sulfonic acid
(IAEDANS) was obtained from Molecular Probes. Other chemicals
were purchased from Sigma-Aldrich and used without further
puriﬁcation.
Protein Preparation. MMOH, MMOB, and MMOR were
prepared as described previously.25 The expression system for
MMOR ferredoxin domain (Fd, residues 1−107) was prepared by
mutating S108 and F109 of wild-type MMOR to stop codons by site-
directed mutagenesis, using primers shown in Table S1. Fd was
expressed and puriﬁed as described previously,26 except that an
additional step with a MonoQ column was employed to separate apo
protein without the iron−sulfur cluster from the holo protein. The
puriﬁed Fd had an A276nm/A330nm ratio of 1.05. MMOB D36C mutant
was prepared as described previously.25 The expression system for the
MMOB Δ2-33 D36C mutant was prepared by site-directed muta-
genesis using MMOB D36C as the template; the primers are shown in
Table S1. The MMOB Δ2-33 D36C protein was expressed and
puriﬁed following the procedure described for wild-type MMOB.25
HDX-MS. HDX-MS was performed essentially as described.27 A 60
pmol portion of MMOH was incubated with Fd for a ﬁnal MMOH:Fd
concentration ratio of 1:6 during deuterium labeling. Under this
condition, >95% of the Fd binding sites on MMOH were saturated,
based on a Kd value of 0.9 μM. All mixtures were incubated for 20 min
at room temperature before deuterium labeling. As a control, MMOH
alone was incubated in 50 mM phosphate buﬀer (pH 7.0) and treated
exactly the same as the Fd-bound protein. Deuterium exchange was
initiated by dilution of each sample with 15-fold 50 mM phosphate
buﬀer (pD 7.0), 99.9% D2O at room temperature. At each deuterium
exchange time point (10 s, 1 min, 10 min, 60 min, 4 h, 6 h, and 8 h),
an aliquot from the exchange reaction was removed and quenched by
adjusting the pH to 2.5 with an equal volume of quench buﬀer (150
mM potassium phosphate buﬀer, H2O). Quenched samples were
immediately frozen on dry ice and stored at −80 °C until analysis.
Several undeuterated control samples were prepared in the same way
as the deuterium-labeled samples and were used for validation of the
peptic peptides of the proteins used in the deuterium labeling
experiments.
Each ﬂash-frozen sample was rapidly thawed and injected into a
Waters nanoACQUITY with HDX Technology (Waters Corp.).28 The
protein samples were digested online using a 2.1 mm × 30 mm
Poroszyme immobilized pepsin cartridge (Applied Biosystems). The
digestion temperature was set to 15 °C and the digestion was
performed for 30 s. The cooling chamber of the ultra-performance
liquid chromatography (UPLC) system, which housed all the
chromatographic elements, was held at 0.0 ± 0.1 °C for the entire
time of the measurements. The injected peptides were trapped and
desalted for 3 min at 100 μL/min and then separated in 14 min by a
5% to 40% acetonitrile:water gradient at 40 μL/min. The separation
column was a 1.0 × 100.0 mm ACQUITY UPLC C18 bridged ethyl
hybrid particles (BEH) column (Waters Corp.) containing 1.7 μm
particles, and the back pressure averaged 8800 psi at 0.1 °C. The
average amount of back-exchange using this experimental setup was
18−25%, based on analysis of highly deuterated peptide standards.
Deuterium levels were not corrected for back-exchange and are
therefore reported as relative;29 however, all comparison experiments
were done under identical experimental conditions, thus negating the
need for a back exchange correction.29 The UPLC step was performed
with protonated solvents, thereby allowing deuterium to be replaced
with hydrogen from side chains and the amino/carboxyl terminus that
exchange much more rapidly than amide linkages.30 All experiments
were performed in triplicate. The average error in determining the
deuterium levels was ±0.1 Da in this experimental setup, consistent
with previously obtained values.31 In order to eliminate peptide
carryover, a wash solution of 1.5 M guanidine hydrochloride, 0.8%
formic acid, and 4% acetonitrile was injected after each run.
Mass spectra were obtained with a Waters XEVO G2 TOF
instrument equipped with standard electrospray ionization source
(Waters Corp.). The instrument conﬁguration was the following:
capillary was 3.2 kV, trap collision energy at 6 V, sampling cone at 35
V, source temperature of 80 °C, and desolvation temperature of 175
°C. Mass spectra were acquired over an m/z range of 100−1900. Mass
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accuracy was ensured by calibration with 500 fmol/μL human [Glu1]-
Fibrinopeptide B and was less than 10 ppm throughout all
experiments. The mass spectra were processed with the software
DynamX 2.0 (Waters Corp.) by centroiding an isotopic distribution
corresponding to the +2, +3, or +4 charge state of each peptide.
Deuteration levels were calculated by subtracting the centroid of the
isotopic distribution for peptide ions of undeuterated protein from the
centroid of the isotopic distribution for peptide ions from the
deuterium-labeled sample. The resulting relative deuterium levels were
automatically plotted versus the exchange-in time. Identiﬁcation of the
peptic fragments was accomplished through a combination of exact
mass analysis and MSE using Identity Software (Waters Corp.). MSE
was performed by a series of low−high collision energies ramping from
5 to 32 V, therefore ensuring proper fragmentation of all the peptic
peptides eluting from the LC system.32 Peptic maps were obtained
with DynamX 2.0 software (Waters Corp.).
Fluorescent Labeling and Fluorescence Anisotropy Meas-
urements. IAEDANS-labeled MMOB D36C and Δ2-33 D36C
mutants were prepared following procedures described previously.25
Concentrations of the labeled proteins were determined by using the
Bradford assay (Bio-Rad). The excitation wavelength was set to 336
nm and emission was monitored at 490 nm. Samples were made in 25
mM MOPS, pH 7.0 buﬀer; the concentration of ﬂuorescently labeled
protein was 1 μM.
Simulations of the Fluorescence Anisotropy Titration
Curves. A competitive model was used to simulate titration curves.
MMOH was considered to have two non-interacting binding sites
(Hsite). The simulation procedures are described as follows, taking the
titration of Fd into 1 μM MMOH and 1 μM IAEDANS-labeled
MMOB as an example. Two equilibria were considered, eqs 1 and 2,
where [Hsite], [B], and [Fd] are the concentrations of free MMOH
binding site, free MMOB, and free Fd; [Hsite-B] and [Hsite-Fd] are the
concentrations of bound MMOB and Fd; [Hsite]total, [B]total, and
[Fd]total are the total concentrations of MMOH binding site (2 μM),
MMOB (1 μM), and Fd (the total amount titrated in). The Kd for the
H−B complex (Kd,H−B) was determined previously to be 0.55 μM;25
several Kd values for the H−Fd complex (Kd,H−Fd) were tested to allow
us to choose the one that best simulated the experimental data.
= −
= − − − − − −
−
−K [H ][Fd]/[H Fd]
([H ] [H B] [H Fd])([Fd] [H Fd])
[H Fd]
d,H Fd site site
site total site site total site
site
(2)
The concentrations [B] and [Hsite−B] were ﬁrst calculated for each
titration point by numerically solving the simultaneous eqs 1 and 2.
These values were then used to calculate the observed ﬂuorescence
anisotropy robs (eq 3), which is the sum of ﬂuorescence anisotropy of
free and bound MMOB weighted by their fractional ﬂuorescence
intensity,33 where rB and rHsite−B are the ﬂuorescence anisotropy of free
and bound MMOB, and f B and fHsite−B are the fractional ﬂuorescence
intensity of free and bound MMOB, respectively. The f B and f Hsite−B
parameters can be expressed in terms of [B], [Hsite−B], and the molar
ﬂuorescence intensity of free and bound MMOB, FB and FHsite−B:
= + − −f F F F[B] /([B] [H B] )B B B site H Bsite (4)
= + −− −f F F F[B] /([B] [H B] )H B B B site H Bsite site (5)
Substituting eqs 4 and 5 into eq 3, the ﬂuorescence anisotropy of
each titration point can be calculated on the basis of [B] and [Hsite−B]
by solving eqs 1 and 2:
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The same simulation procedures were followed for the titration of
Fd into 1 μM MMOH and 1 μM IAEDANS-labeled MMOB Δ2-33.
The Kd value of 2.67 μM for the H−B Δ2-33 complex determined in
this study was used for the simulation (Figure S3). Several Kd values
(0.9, 2, and 6 μM) for the H−Fd complex (Kd,H−Fd) were tested to see
which one best ﬁts the experimental data.
Chemical Cross-Linking. To a mixture of 10 μM MMOH, 20 μM
MMOR, and 0−120 μMMMOB in 50 mM MOPS buﬀer, pH 7.0, was
added 10 mM cross-linker EDC. The reaction was incubated at room
temperature for 10 min and then quenched by adding an equal volume
of SDS loading buﬀer.22 The reaction was analyzed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Electron Transfer Studies. The electron transfer kinetics of
sMMO were studied by stopped-ﬂow optical spectroscopy at 15 °C.
The tubing and syringes of the Hi-Tech Scientiﬁc SF-61 DX2 double-
mixing stopped-ﬂow instrument were made anaerobic by ﬁrst ﬂushing
and then incubating with 15 mM anaerobic sodium dithionite solution
for 3 h, followed by ﬂushing with 25 mM anaerobic MOPS buﬀer, pH
7.0 right before use. The following steps were performed inside of a
glovebox with an O2 level of less than 0.5 ppm. To investigate electron
transfer from chemically reduced reductase, 40 μM degassed Fd or
MMOR was titrated with 3 mM sodium dithionite until the absorption
at 405 nm no longer changed, and the resulting sample was then
loaded into a gastight syringe. A 20 μM quantity of MMOH, or 20 μM
MMOH premixed with 40 μM MMOB in the presence or absence of
10 μM MMOR, was degassed and sealed in another gastight syringe.
To study electron transfer from NADH, a 40 μM solution of anaerobic
NADH was sealed in one syringe; 20 μM MMOH premixed with 40
μM MMOR in the presence/absence of 40 μM MMOB was sealed in
another syringe. The syringes were then taken out from the glovebox
and connected to the stopped-ﬂow instrument. Equal volumes of
reagents from each syringe were rapidly mixed by the stopped-ﬂow
instrument, and the electron transfer kinetics were monitored by
recording the absorbance change at 470 or 458 nm. Data were ﬁt by
two (when chemically reduced Fd or MMOR was used as the electron
source) or three (when NADH was used as the electron source)
exponentials, and eﬀective electron transfer rates were calculated as
weighted averages of individual electron transfer rate constant.
■ RESULTS AND DISCUSSION
HDX-MS Study of MMOH. HDX-MS is a powerful tool for
probing protein structure, dynamics, and the binding inter-
face.34,35 The rationale behind HDX-MS relies on protein
backbone amide protons that are in constant exchange with
solvent protons, or deuteriums if in deuterated solvent. The
number of exchangeable protons and their rates of exchange
depend on factors such as pH, temperature, chemical
environment, and the three-dimensional protein architec-
ture,30,34−37 thus reﬂecting the structure and dynamics of the
protein. Typically, protein backbone amide protons exchange
rapidly with deuterons if they are involved in weak or
suboptimal hydrogen bonds, reside at/near the surface, or are
readily accessible to the solvent; the exchange rates are slower if
they are involved in strong intramolecular hydrogen bonds
and/or are less accessible to solvent.38 HDX-MS has also been
successfully applied to determine protein−protein binding sites,
= −
= − − − − − −
−
−K [H ][B]/[H B]
([H ] [H B] [H Fd])([B] [H B])
[H B]
d,H B site site
site total site site total site
site
(1)
= + − −r r f r fobs B B H B H Bsite site (3)
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based on the reduced solvent exposure in regions that
constitute the binding interface.35,36,40
Here we ﬁrst probed the dynamics of MMOH alone by
HDX-MS. MMOH is a 251.3 kDa homodimer that consists of
three protomer subunits in each monomer: α (60.6 kDa), β
(45.1 kDa), and γ (19.8 kDa). Upon pepsin digestion, 165
overlapping MMOH peptic peptides were detected, covering
93.9%, 93.5%, and 96.4% of the sequences of the α-, β-, and γ-
subunits, respectively (Figure S1). The deuterium incorpor-
ation and protein dynamics were followed from 10 s up to 8 h.
All the peptic peptides that were followed by HDX-MS are
displayed in Figure S2. Most of these peptides showed low
deuterium uptake even after an 8 h incubation in deuterated
buﬀer (Figure 2). The data indicate very slow dynamics in most
of the three subunits of the homodimer, suggesting that the
protein is very rigid and not undergoing breathing movements
indicative of a dynamic and solvent exposed structure.29,35
Amide backbone hydrogens involved in hydrogen-bonding
interactions in secondary structural elements such as α-helices
and β-sheets exhibit slow exchange rates.41 Therefore, the low
deuterium uptake is consistent with the high helical content of
MMOH.15,16,39 The α and β-subunits are more protected from
exchange compared with the γ-subunit, the peptides of which
seem to indicate a more accessible and dynamic structure
(Figure 2).
HDX-MS Study of the MMOH−Fd Complex. We next
used HDX-MS to locate regions of MMOH that show
diﬀerences in exchange upon binding to the ferredoxin domain
(Fd, residues 1−107, 11.8 kDa) of MMOR. MMOR is
characterized by a modular structure containing both FAD
and ferredoxin domains.42 The two isolated domain proteins
both have stable structures43,44 and retain the biochemical
properties of the two domains in full-length MMOR.42 Electron
transfer to the diiron(III) centers in the hydroxylase involves
ﬁrst, NADH reductions of the oxidized FAD cofactor to its
hydroquinone form, followed by the [Fe2S2] cluster in the Fd
sequentially shuttling two electrons from the reduced FAD
cofactor to the diiron center in MMOH.12,23,45 The Fd protein
is a smaller yet competent model of MMOR for studying
electron transfer as well as binding to MMOH.26
Among the 165 detected peptic peptides of MMOH in the
presence of Fd (Figure S2), six peptides derived from the α-
subunit and three from the β-subunit exhibited lower
deuterium uptake compared with samples without Fd (Figures
3 and S2), covering residues 70−88 and 236−255 of the α-
subunit, and residues 37−48 of the β-subunit. The diﬀerences
in deuterium uptake were visible after ∼10−60 min deuteration
but not at earlier time points, possibly because the exchange
rates in the absence of Fd were already very slow due to stable
H-bonds in the α-helices. In the presence of Fd the reduced
solvent exposure at the binding site modestly reduced the
exchange rates. The diﬀerences in deuterium uptake in the
presence and absence of Fd were subtle even at longer
incubation times (up to 8 h exchange), but were consistent in
the set of overlapping peptides. Typically, diﬀerences in
deuteration greater than 0.4 Da but less than 1 Da are
considered subtle. The experiments were performed in
triplicate, and the average error of the measurements was
±0.1 Da. All other MMOH peptic peptides exhibited the same
deuterium uptake in the presence or absence of Fd (Figure S2).
Figure 2. Summary of HDX-MS data for free MMOH in solution at four time points. The HDX-MS data are mapped onto PDB entry 1MTY,39 with
the color code indicated for deuteration times shown at the bottom of each image. The HDX-MS data are shown only on one monomer; the second
monomer is represented in sand color.
Figure 3. Hydrogen−deuterium exchange kinetics for four represent-
ative peptides that showed diﬀerent deuterium uptake in the presence
(blue traces) or absence (red traces) of Fd: (a) residues 70−81, α-
subunit; (b) residues 82−88, α-subunit; (c) residues 237−242, α-
subunit; and (d) residues 40−47, β-subunit. The largest number on
the y-axis represents the maximum amount of deuterium that can be
incorporated in each peptic peptide.
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We then mapped the peptides that showed decreased
deuterium uptake in the presence of Fd onto the crystal
structure of MMOH (PDB entry 4GAM). These peptides
cluster in the canyon region at the α2β2 interface, representing a
possible Fd binding site (Figure 4a). This region includes the
area closest to the diiron center from the protein surface, a
preferred binding site for the iron−sulfur cluster of the
reductase in order to facilitate fast electron transfer. This
binding site determined by HDX-MS rationalizes the seemingly
conﬂicting results of previous chemical cross-linking studies.
Because the binding site consists of residues from both α- and
β-subunits, MMOR can cross-link to either the α-subunit (for
sMMO isolated from Methylococcus capsulatus (Bath))22 or the
β-subunit (for sMMO isolated from Methylosinus trichosporium
OB3b).21 It is unlikely that sMMOs isolated from diﬀerent
species have diﬀerent reductase binding sites. The diﬀerent
cross-linking results are most likely due to diﬀerent
distributions of carboxyl groups and amino groups that are
required to be in close proximity for the cross-linking mediated
by EDC.
To validate the HDX-MS-determined Fd binding site, we
performed computational docking using the ClusPro serv-
er.46−49 The structure of Fd (residues 1−98, PDB ID 1J4Q)
previously determined by solution-state NMR spectroscopy43
and the crystal structure of MMOH (PDB ID 4GAM)39 were
used as input structures, and the NMR-determined Fd residues
involved in binding to MMOH43 were used as docking
constraints. The results show that Fd covers the HDX-MS-
determined binding surface (Figure 4b). The β-subunit
peptides involved in binding (yellow region in Figure 4)
seem uncovered in the docked structure (Figure 4b), but upon
a closer examination residues 45−48 inside the canyon were
found to be in close contact with Fd. The docking result is
therefore in full agreement with the HDX-MS data.
Implications for Electron Transfer from MMOR to
MMOH. A close examination of the docked MMOH−Fd
complex reveals that the diiron active site of MMOH is
approximately 14 Å away from the [Fe2S2] cluster of Fd, a
favorable distance for electron transfer.24 Consistent with
HDX-MS results, the docked model reveals that Fd covers the
pore region of MMOH, which we previously proposed as the
proton transfer pathway from the MMOH surface to its diiron
center.20,50 Residue E240 in the MMOH α-subunit, the gating
residue of the pore, is situated midway between the [Fe2S2]
cluster of Fd and the diiron center of MMOH (Figure 4c).
Previously, this residue was found to shift its conformation
toward the protein interior upon MMOB binding, closing the
pore and possibly bringing in a proton to the diiron active
site.20 We propose that an identical conformational change
occurs when MMOR binds to MMOH during electron transfer
from the Fd [Fe2S2] cluster to the carboxylate-bridged diiron
center, providing the mechanism for proton-coupled electron
transfer.
Binding Competition between the Reductase and the
Regulatory Protein. Strikingly, the Fd binding site
determined here overlaps largely with that of MMOB as
previously determined by the crystal structure of the MMOH−
2MMOB complex. In particular, this structure reveals that the
core of MMOB docks into the canyon region, covering the very
same area where we now conclude Fd binds, while the N-
terminal tail of MMOB binds to an adjacent location on
MMOH, on the surface of helices H and 4 of the α-subunit,
adopting a ring-like conformation (Figure 4d).20 This
observation requires the Fd of MMOR and the core of
MMOB compete for the same binding site in the canyon of
MMOH.
To test this possibility, we ﬁrst investigated the binding
competition between Fd and the core of MMOB by
ﬂuorescence anisotropy titrations. The MMOB core was
prepared by truncating the N-terminal tail at residue 33 (Δ2-
33), and a cysteine mutation D36C was introduced in order to
attach the ﬂuorophore IAEDANS. The N-terminal truncated
MMOB (designated MMOB Δ2-33) is still able to bind to
MMOH but with lower aﬃnity (Kd = 2.67 μM, Figure S3; Kd =
0.55 μM for the full-length MMOB25). To characterize the
binding competition, Fd was titrated into a mixture of 1 μM
MMOH and 1 μM IADEANS-labeled MMOB Δ2-33. The
ﬂuorescence anisotropy decreased steadily as increasing
amounts of Fd were added (Figure 5a), indicating displacement
of N-terminal truncated MMOB by Fd from MMOH (Scheme
1a). The titration curve could be simulated by assuming that
the N-terminal truncated MMOB and Fd compete for the same
binding sites on MMOH (MMOHsite, one on each side of
MMOH), and an apparent Kd value of 2 μM was obtained for
the MMOH−Fd complex on the basis of the simulations
(Figure 5a).
The apparent Kd value increased to 6 μM for the Fd−
MMOH complex when the titration experiment was repeated
with the full-length MMOB labeled with IAEDANS (Figure
5b), indicating that Fd is less eﬀective in displacing full-length
MMOB. This result is an expected consequence of the
additional binding site of the N-terminal tail of MMOB on
the surface of helices H and 4 of the MMOH α-subunit,20 a
binding region not shared with Fd. It is possible that the N-
terminal tail serves as an anchor attached to the surface of
Figure 4. Fd and MMOB binding sites on MMOH. (a) MMOH
peptides that showed decreased deuterium uptake in the presence of
Fd are mapped onto the crystal structure of MMOH (PDB ID
4GAM). (b) A computationally docked MMOH−Fd complex. (c) A
closer view of the binding interface in the docked model: the [Fe2S2]
cluster of Fd, MMOH residues at the binding interface, and the diiron
center of MMOH, viewed from the top of the ﬁgure. (d) The crystal
structure of MMOH-2MMOB, showing that MMOB covers the Fd
binding site. MMOH is colored in cyan; binding site peptides of the α-
subunit in orange and those of the β-subunit in yellow; Fd in red; and
MMOB in purple.
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MMOH, such that, when Fd displaces the core of MMOB from
the canyon, MMOB does not completely dissociate from
MMOH (Scheme 1b).20 A simple competitive binding model
would therefore no longer apply to the component interactions
in this case. Similar results were obtained by using the full-
length MMOR as the titrant. An apparent Kd value of 8 μM for
the MMOH−MMOR complex is required to ﬁt the titration
curve using a competitive binding model (Figure S4),
considerably larger than the 0.9 μM Kd value previously
determined23 for the MMOH−MMOR complex in the absence
of MMOB.
These results clearly demonstrate that both Fd and the full-
length MMOR are able to displace MMOB, in particular the
core of MMOB, from MMOH. Conversely, MMOB can
displace MMOR from MMOH. This property was demon-
strated by studying the eﬀect of MMOB on MMOR cross-
linking to MMOH. As shown in Figure 5c, MMOR forms
cross-links to the MMOH α-subunit in the presence of EDC, as
demonstrated previously;22 the yield of this cross-link decreases
in a dose-dependent manner as the MMOB concentration
increases from 0 to 6 equiv relative to the MMOR
concentration, indicating that MMOB blocks MMOR binding,
and thus its cross-linking, to MMOH. A similar ﬁnding was
reported for sMMO from M. trichosporium OB3b.21
MMOB Inhibits Electron Transfer. The determination of
component protein binding sites on the hydroxylase and their
binding competition form a basis for understanding the role of
the regulatory protein in electron transfer reactions of sMMO.
Previously, MMOB was proposed to facilitate electron transfer
from MMOR to MMOH, and this eﬀect was ascribed to
formation of a hypothetical MMOH−2MMOB−2MMOR
ternary complex.23 It was hypothesized that the increased
electron transfer exhibited by this ternary complex is due to a
conformational change of MMOH induced by MMOR.
Considering the substoichiometric concentration of MMOR
found in vivo and used during activity assays,23,51 it was further
proposed that such conformational changes are retained
throughout the catalytic cycle even after MMOR dissociates
from the ternary complex.26 Considering our current ﬁnding
that the core of MMOB and the Fd of MMOR compete for
binding to the canyon of MMOH, these proposals are deemed
unlikely. Because MMOB can inhibit MMOR binding to the
canyon, MMOB would inhibit electron transfer as well.
To test experimentally whether MMOB increases the
electron transfer rate, and whether pre-equilibrating MMOR
with other protein components would result in such an
increase, we designed two sets of single-turnover, single-mixing
stopped-ﬂow experiments. In the ﬁrst set, the electron transfer
reactions were initiated by mixing 2 equiv of chemically
reduced Fd to (i) 1 equiv of oxidized MMOH alone, (ii) 1
equiv of oxidized MMOH equilibrated with 2 equiv of MMOB,
and (iii) 1 equiv of oxidized MMOH equilibrated with 2 equiv
of MMOB as well as 0.5 equiv of MMOR (Figure 6a). The
Figure 5. Experimental evidence for MMOR and MMOB binding
competition. (a,b) Titrating Fd into 1 μM MMOH and 1 μM
IADEANS-labeled N-terminal truncated (Δ2−33) MMOB (a) or full-
length MMOB (b). The titration curves are simulated assuming Kd =
0.9, 2, and 6 μM for the MMOH−Fd complex; Kd = 2 and 6 μM best
ﬁt the experimental data in (a) and (b), respectively. (c) MMOB
inhibits MMOR cross-link to MMOH. EDC was used as the cross-
linking reagent, and 0, 1, 2, 4, and 6 equiv MMOB relative to MMOR
were added to a mixture of 10 μM MMOH and 20 μM MMOR. The
cross-linking reaction mixtures were resolved by SDS-PAGE, and
bands corresponding to the MMOR−α-subunit cross-linking product
are shown.
Scheme 1. Schematic Representations for MMOR
Ferredoxin Domain (Red) and MMOB (Purple) Binding
Competition for the Canyon of MMOH (Gray): (a) Binding
Competition between Fd and MMOB Core (MMOB Δ2-33)
and (b) Binding Competition between Fd and Full-Length
MMOBa
aIn the binding competition between Fd and full-length MMOB (b),
Fd may displace the core of MMOB from the canyon, but the N-
terminal tail may still bind to MMOH.
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reactions were monitored at 470 nm, which increases in
intensity as electrons are transferred to the MMOH diiron sites
from the reduced [Fe2S2] clusters. The previous proposal
would predict that case (iii), where all three components were
pre-mixed and equilibrated, would exhibit the fastest electron
transfer rate. The actual results (Figure 6b), however, showed
that reaction (i) displays the fastest electron transfer rate.
Including MMOB in reactions (ii) and (iii) signiﬁcantly
retarded the electron transfer reaction, even when MMOR
was added and pre-equilibrated with other components. The
eﬀective electron transfer rates under diﬀerent conditions are
summarized in Table 1. These experiments were repeated using
chemically reduced full-length MMOR as the reductant, and
the same trend was observed (Figure S5).
In the second set of experiments, the electron transfer
reaction was initiated by mixing 2 equiv of NADH with (i) 1
equiv of oxidized MMOH and 2 equiv of MMOR and (ii) 1
equiv of oxidized MMOH, 2 equiv of MMOB, and 2 equiv of
MMOR (Figure 7a). The reactions were monitored at 470 nm,
where the absorption ﬁrst decreased due to the reduction of the
FAD cofactor by NADH and the subsequent intra-MMOR
electron transfer to the [Fe2S2] cluster.
12 The absorption at this
wavelength then increased, as electrons were transferred from
these cofactors to the diiron centers in MMOH. The previous
proposal would predict that reaction (ii), which had all three
protein components pre-equilibrated, would display the faster
electron transfer rate, but in fact it is slower (Figure 7b), again
demonstrating the inhibitory eﬀect of MMOB on electron
transfer (Table 1).
Binding Competition: A Possible Mechanism for
Modulating Electron Transfer. The inhibitory eﬀect of
MMOB on electron transfer is in full agreement with our
ﬁnding that the core of MMOB shares a binding site on
MMOH with the Fd of MMOR such that MMOB inhibits
MMOR binding. Although electron transfer is retarded, it is still
much faster than the rate of substrate turnover (kcat = 0.1 s
−1 at
15 °C using propylene as substrate). The advantage of such
competitive binding is that it provides a mechanism for
modulating electron transfer during catalysis. By ﬁne-tuning the
aﬃnity of MMOR and MMOB for the canyon region of
MMOH, the binding of MMOR can be inhibited during
dioxygen activation, preventing undesired electron transfer that
could quench activated dioxygen intermediate species. Such
quenching is suggested by oxidase activity displayed by MMOH
and MMOR in the absence of MMOB.23
The modulation of electron transfer exhibited by the MMOB
regulatory protein is most likely a feature common to other
BMM enzymes. These enzymes share conserved protein
sequences as well as structures,1,2 and, like sMMO, their
regulatory proteins also bind to an analogous canyon region of
the hydroxylase, as illustrated in the X-ray structures of the
protein complexes in PH18 and T4mO,19 blocking the shortest
pathway to the hydroxylase diiron center from its surface. The
reductase may therefore need to compete with the regulatory
protein for binding in order to deliver electrons to the diiron
centers in these enzymes as well. In disagreement with this
hypothesis, previous studies of PH and ToMO reported
accelerated electron transfer in the presence of the regulatory
protein.52 These electron transfer rates, however, were
determined in steady-state assays in the absence of substrates,
by measuring NADH consumption. Under these conditions,
Figure 6. MMOB inhibits electron transfer, using chemically reduced
Fd as the electron source. (a) Schematic diagrams for the ﬁrst set of
experiments. (b) Electron transfer kinetic curves. T = 15 °C.
Table 1. Eﬀective Electron Transfer Ratesa
syringe 1 syringe 2
eﬀective electron
transfer rate (s−1)
2Fd, reduced MMOH 76.1 ± 1.3
2Fd, reduced MMOH−2MMOB 17.0 ± 0.7
2Fd, reduced MMOH−2MMOB−0.5MMOR 18.3 ± 0.8
2NADH MMOH−2MMOR 14.0 ± 0.4
2NADH MMOH−2MMOB−2MMOR 3.52 ± 0.31
aElectron transfer reactions were initiated by mixing the reagent in
syringe 1 with protein(s) in syringe 2 in single-mixing stopped-ﬂow
experiments (setups also shown in Figures 6a and 7a).
Figure 7. MMOB inhibits electron transfer, using NADH as the
electron source. (a) Schematic diagrams for the second set of
experiments. (b) Electron transfer kinetic curves.
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the NADH consumption rate depends on the oxidase activity of
the hydroxylase, and the accelerated NADH consumption in
the presence of the regulatory component is most likely due to
increased oxidase activity and not an indication of accelerated
electron transfer.
■ CONCLUSIONS
Using HDX-MS, the binding site for the ferredoxin domain of
MMOR was determined to be in the canyon of MMOH, the
same region where the core of the MMOB regulatory protein
binds. This ﬁnding is consistent with previous chemical cross-
linking results and the current computational docking study, as
well as a series of binding competition assays. MMOB inhibits
MMOR binding to the canyon as well as the electron transfer
that leads to reduction of the hydroxylase. The previous
proposals that MMOB increases the electron transfer rate when
all three components are pre-equilibrated has been tested
experimentally and proved to be invalid. Regulatory proteins of
other BMM enzymes may similarly share binding sites with
their reductases and inhibit electron transfer.
Such binding competition would provide a control
mechanism for electron transfer in BMM enzymes. To initiate
the catalytic cycle, the reductase displaces the regulatory
protein from the canyon of the hydroxylase, reducing the diiron
center from diiron(III) to diiron(II); the regulatory protein
then re-binds to the canyon and displaces the reductase,
initiating O2 activation and substrate oxidation. The binding
aﬃnities of the component proteins may be ﬁne-tuned so that
the reductase is unable to displace the regulatory protein at this
step, preventing quenching of activated oxygen intermediates
P*, Hperoxo, and Q.
53 At the end of the catalytic cycle, the diiron
center returns to the diiron(III) state, and the reductase can
bind again to the canyon, priming the enzyme for the next cycle
of catalysis.
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